Scholarlink

<p>Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis. Existing treatments for RA have serious side effects. Corosolic acid (CRA) is a natural pentacyclic triterpenoid compound with anti-inflammatory potential. However, the effect of CRA on inflammation, its possible mechanism of action, and potential therapeutic effect on RA are not well understood. This study explored the CRA mechanism of treatment action on RA by evaluating the NF-κB/PI3K/AKT signaling pathway in vitro and in vivo. In vitro, fibroblast like synovial cells (FLS) from collagen induced arthritis (CIA) rats were assessed. ELISA, western blot, and immunofluorescence techniques demonstrated CRA (6&#xa0;µg/mL) to significantly inhibit FLS secretion of TNF-α, IL-1β, and IL-6, as well as downregulate the phosphorylation of NF-κB and PI3K/AKT pathways. Inhibition experiments demonstrated that NF-κB activation was upstream of PI3K/AKT activation. In vivo, after 21 days of oral administration of CRA (10&#xa0;mg/kg) to CIA rats, the arthritis score, organ index, and serum inflammatory factor levels were significantly decreased. Histopathologic analysis and Micro-CT showed that CRA reduced synovial hyperplasia and bone erosion. These results indicated that CRA exerted anti-inflammatory effects by inhibition of the NF-κB/PI3K/AKT signaling pathway, providing a potential new treatment strategy for RA patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Corosolic acid alleviates rheumatoid arthritis by down regulation of the NF-κB/PI3K/AKT signaling pathway

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月28日

查看全文
  • Xian Jiang,
  • Weixi Liu,
  • Shanqi Xu,
  • Xinling Ni,
  • Weiding Cui,
  • Zhicheng Yang,
  • Xiaodong Chen,
  • Liqun Wang,
  • Ruiping Liu

摘要

Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis. Existing treatments for RA have serious side effects. Corosolic acid (CRA) is a natural pentacyclic triterpenoid compound with anti-inflammatory potential. However, the effect of CRA on inflammation, its possible mechanism of action, and potential therapeutic effect on RA are not well understood. This study explored the CRA mechanism of treatment action on RA by evaluating the NF-κB/PI3K/AKT signaling pathway in vitro and in vivo. In vitro, fibroblast like synovial cells (FLS) from collagen induced arthritis (CIA) rats were assessed. ELISA, western blot, and immunofluorescence techniques demonstrated CRA (6 µg/mL) to significantly inhibit FLS secretion of TNF-α, IL-1β, and IL-6, as well as downregulate the phosphorylation of NF-κB and PI3K/AKT pathways. Inhibition experiments demonstrated that NF-κB activation was upstream of PI3K/AKT activation. In vivo, after 21 days of oral administration of CRA (10 mg/kg) to CIA rats, the arthritis score, organ index, and serum inflammatory factor levels were significantly decreased. Histopathologic analysis and Micro-CT showed that CRA reduced synovial hyperplasia and bone erosion. These results indicated that CRA exerted anti-inflammatory effects by inhibition of the NF-κB/PI3K/AKT signaling pathway, providing a potential new treatment strategy for RA patients.